Company Overview of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planne...
75 Kneeland Street
Boston, MA 02111
Key Executives for Paratek Pharmaceuticals, Inc.
Chairman of the Board and Chief Executive Officer
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $10.4K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.
Paratek Pharmaceuticals, Inc. Key Developments
Paratek Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 15 15
Paratek Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the year, the company reported loss from operations was $10,633,000 against $931,000 a year ago. Net loss was $10,633,000 against $1,211,000 a year ago. Net loss attributable to common stockholders was $10,633,000 or $0.74 per basic and diluted share against $1,413,000 or $20.93 per basic and diluted share a year ago.
Paratek Pharmaceuticals, Inc. Approves Amendments to Amended and Restated Bylaws
Apr 16 15
On April 10, 2015, the Board of Directors of Paratek Pharmaceuticals, Inc. approved amendments to Amended and Restated Bylaws, or the New Bylaws, which supersede and replace prior Amended and Restated Bylaws, effective immediately. The New Bylaws, among other things, provide that: To be timely, written notice of nominations for election to the Board of Directors and proposals to be included in proxy materials, to be properly brought before an annual meeting by a stockholder, must be received at principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year’s annual meeting, notice by the stockholder must be received not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made; The Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on their behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against them arising pursuant to the Delaware General Corporation Law, certificate of incorporation or bylaws; or any action asserting a claim against the company that is governed by the internal affairs doctrine.
Paratek Pharmaceuticals, Inc. Announces Financial Results for the Year Ended December 31, 2014
Apr 2 15
Paratek Pharmaceuticals, Inc. announced financial results for the year ended December 31, 2014. For the year, the company reported a net loss of $19.8 million, or $7.82 per share, compared to a net loss of $11.4 million, or $185.13 per share, for the year ended December 31, 2013. Revenue in 2014 was $4.3 million, consisting of a $4.0 million milestone payment from Actavis Plc earned during the fourth quarter for the start of a Phase 3 clinical trial for sarecycline and recognition of $0.3 million in deferred revenue upon the termination of a collaborative research, development and commercialization agreement with a leading global animal health provider. Loss from operations was $17,835,000 compared to $7,540,000 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions